Our findings also demonstrate that co-treatment with LSD1i and the JAK1/2 inhibitor ruxolitinib exerts synergistic in vitro lethality and exhibited superior in vivo efficacy than LSD1i monotherapy in a mouse xenograft model of post-MPN sAML. The gene discussed is JAK1; the disease is myeloproliferative neoplasm.